AMRI Included in BARDA CDMO Network in Support of COVID-19 Pandemic Response in the U.S.
January 11, 2021
ALBANY, N.Y.–(BUSINESS WIRE)–Albany Molecular Research, Inc. (AMRI), a leading global provider of advanced contract research, development and manufacturing solutions, today announced its Albuquerque, New Mexico, facility has been approved for inclusion in the Biomedical Advanced Research and Development Authority (BARDA) contract development and manufacturing organization (CDMO) network. The network is part of a comprehensive effort by the U.S. government to improve preparedness capabilities.
AMRI’s Albuquerque location includes a large-scale fill and finish facility, currently supporting COVID-19 vaccine production. Inclusion in the network recognizes AMRI’s pandemic preparedness, its existing support of COVID-19 vaccine production, experience in government contracting and its ability to support further BARDA contract work at Albuquerque.
“We are proud to join the BARDA CDMO network, reflecting our commitment to play a vital role in the COVID-19 pandemic response,” said John Ratliff, CEO, AMRI. “AMRI’s track record of navigating complex environments, based on our broad capabilities from R&D through manufacturing, enables us to contribute to this critical moment in improving health.”
Sites included in BARDA’s CDMO network must be vetted and prequalified for the immediate production of medical countermeasures in the event of a health threat in the U.S. BARDA is a U.S. government organization, overseen by the Health and Human Services Assistant Secretary for Preparedness and Response.
AMRI, a contract research development and manufacturing organization, partners with the pharmaceutical and biotechnology industries to improve patient outcomes and quality of life. AMRI’s team combines scientific expertise and market-leading technology to provide a complete suite of solutions in discovery, development, analytical services, and API and drug product manufacturing.
More from Curia
December 5, 2023
Curia Recognized on India Pharma Outlook’s 2023 List of Top 10 CDMO Companies in India
Curia recognized as one of the top 10 CDMOs in India acknowledging the contributions of Curia’s Aurangabad and Hyderabad sites.